Literature DB >> 9123870

HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity.

F Mustafa1, J F Richmond, R Fernandez-Larsson, S Lu, R Fredriksson, E M Fenyö, M O'Connell, E Johnson, J Weng, J C Santoro, H L Robinson.   

Abstract

Seven envelope regions from two series of patient isolates have been molecularly cloned and analyzed for replication phenotypes and immunogenicity. Growth potential was analyzed for env sequences substituted into an HIV-1-NL4-3 backbone (NL4-3/env recombinants). Immunogenicity studies were conducted on secreted monomeric (gp120) and oligomeric (gp140) forms of the Envs using Env-expressing plasmid DNAs for immunizations. The env regions of the patient isolates conferred a spectrum of replication kinetics and cytotropisms on the NL4-3/env recombinants. Both patient series included non-syncytium-inducing viruses with no ability to grow on T-cell lines, and highly syncytium inducing viruses which grew well on T-cell lines. These differences in growth potential did not correlate with the ability of the DNA-expressed Envs to raise antibody in rabbits. Rather, the relative immunogenicity of the Envs was patient and form specific. The Envs from patient 5 raised higher titers of antibody than the Envs from patient 6. For each primary Env, the gp120 form of the Env raised higher titers of antibody than the gp140 form. Thus, structural features of Env that affect replication do not necessarily affect the ability to raise antibody.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9123870     DOI: 10.1006/viro.1997.8445

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.

Authors:  T M Ross; Y Xu; T D Green; D C Montefiori; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

Review 2.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

3.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.

Authors:  A Björndal; H Deng; M Jansson; J R Fiore; C Colognesi; A Karlsson; J Albert; G Scarlatti; D R Littman; E M Fenyö
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 4.  A vaccine for HIV type 1: the antibody perspective.

Authors:  D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

5.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Authors:  Joseph F Bower; Kelly L Sanders; Ted M Ross
Journal:  Curr HIV Res       Date:  2005-04       Impact factor: 1.581

6.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 7.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

8.  Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Authors:  J F Richmond; S Lu; J C Santoro; J Weng; S L Hu; D C Montefiori; H L Robinson
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

Authors:  Thomas D Green; David C Montefiori; Ted M Ross
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response.

Authors:  Richard Sallie
Journal:  Virol J       Date:  2007-03-13       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.